TNO155 is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). TNO155 has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Batoprotafib (TNO155) is a highly potent, selective, and orally active allosteric inhibitor of wild-type SHP2, with an IC50 of 0.011 µM. It holds promise for investigating RTK-dependent malignancies, particularly advanced solid tumors [1]. |
Animal study | The oral bioavailability in mouse, rat, and monkey is 78%, 86%, and 60%, respectively [1].Batoprotafib (20 mg/kg; oral administration; twice daily for 40 days) suppresses tumor growth and exhibits enhanced efficacy when administered in combination with Dabrafenib plus Trametinib in nude mice harboring HT-29 xenografts [2].Batoprotafib (7.5 mg/kg; pO.; b.iD. or qD. for 36 days) in combination with JDQ-443 (100 mg/kg; pO.; qD.) enhances the efficacy of JDQ443 alone in KRASG12C-mutated cell-derived (CDX) models in nude mice [3]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.37mL 0.47mL 0.24mL |
11.85mL 2.37mL 1.18mL |
23.70mL 4.74mL 2.37mL |
CAS号 | 1801765-04-7 |
分子式 | C18H24ClN7OS |
分子量 | 421.95 |
SMILES Code | N[C@@H]1[C@@H](OCC12CCN(CC2)C3=NC(N)=C(N=C3)SC4=C(C(N)=NC=C4)Cl)C |
MDL No. | MFCD32693919 |
别名 | TNO155 |
运输 | 蓝冰 |
InChI Key | UCJZOKGUEJUNIO-IINYFYTJSA-N |
Pubchem ID | 118238370 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|